Comparative Pharmacology
Head-to-head clinical analysis: AZMACORT versus BREZTRI AEROSPHERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZMACORT versus BREZTRI AEROSPHERE.
AZMACORT vs BREZTRI AEROSPHERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to produce anti-inflammatory and immunosuppressive effects.
Budesonide is a corticosteroid with anti-inflammatory activity; glycopyrrolate is a muscarinic receptor antagonist that inhibits cholinergic bronchoconstriction; formoterol is a long-acting beta2-adrenergic agonist that relaxes bronchial smooth muscle.
Two inhalations (200 mcg) three to four times daily or four inhalations (400 mcg) twice daily via oral inhalation.
Two inhalations (each containing budesonide 160 mcg, glycopyrrolate 18 mcg, and formoterol fumarate 4.8 mcg) orally twice daily.
None Documented
None Documented
Terminal elimination half-life of 3-4 hours for the inhaled route; prolonged in hepatic impairment.
Terminal elimination half-life: budesonide 2.5–3.1 hours, glycopyrrolate 0.5–1.0 hour (inhalation) or 1.3–1.6 hours (IV), formoterol approximately 10 hours after inhalation. Clinical context: Budesonide's short half-life supports once-daily dosing with the co-suspension delivery technology providing prolonged lung retention. Glycopyrrolate's short half-life necessitates twice-daily dosing; formoterol's longer half-life allows twice-daily administration.
Primarily fecal (60-80%) and renal (10-20%) as metabolites; unchanged drug <5% in urine.
Following oral inhalation, budesonide (corticosteroid component) is primarily excreted in urine (60%) and feces (40%) as metabolites. Glycopyrrolate (LAMA) is excreted predominantly unchanged in urine (70%) and feces (30%) after IV administration, with renal excretion as the main route. Formoterol (LABA) is extensively metabolized; approximately 62% of a radiolabeled dose appears in urine and 24% in feces. For the fixed-dose combination, renal elimination of unchanged glycopyrrolate is a major clearance pathway.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/LAMA/LABA Combination